COMMUNIQUÉS West-GlobeNewswire

Best Vyvanse Alternative Over the Counter for ADHD - Natural Vyvanse Substitute - Noocube
10/05/2025
London, May 10, 2025 (GLOBE NEWSWIRE) -- Vyvanse is a prescription medication that is used to treat ADHD symptoms, but it can be expensive and some people don't like the idea of taking a drug class medicine or stimulant [...]
Akero Therapeutics annonce la publication de l’essai de phase 2b SYMMETRY dans le New England Journal of Medicine
10/05/2025
Les résultats confirment le bénéfice potentiel de l’éfruxifermine (EFX) pour déclencher une amélioration de la fibrose chez les patients atteints de cirrhose compensée (fibrose F4) due à une MASH ; les données à 96 [...]
MEDVi Under Review: Best GLP-1 Semaglutide & Terzepatide Compound Solution for Personalized Weight Loss
10/05/2025
A Comprehensive Review of MEDVi’s Personalized GLP-1 Weight Loss Solutions Featuring Affordable Compounded Semaglutide and Tirzepatide Delivered via Telehealth New York, May 10, 2025 (GLOBE NEWSWIRE) -- In This Article [...]
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
10/05/2025
Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress 65% of patients with clinically significant portal hypertension (CSPH) [...]
Sumatra Slim Belly Tonic Reviews: 2025 Real User Reviews Analyzed & Verified (Blue Tonic for Weight Loss)
10/05/2025
LOS ANGELES, May 10, 2025 (GLOBE NEWSWIRE) -- Losing weight these days can feel more difficult than ever. Despite trying countless diets, workout routines, and the latest supplements, many people still struggle with [...]
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
10/05/2025
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in [...]
4 Best Supplements for Muscle Growth in 2025 - Legal Steroid Alternatives & Bodybuilding Supplements for Bulking and Strength - Wolfson Brands
10/05/2025
Glasgow, May 10, 2025 (GLOBE NEWSWIRE) -- The best legal supplements for muscle growth is presented by Wolfson Brands Building serious muscle isn’t just about hitting the gym hard, it’s about giving your body the right [...]
Best Fat Burners For Men 2025: Top Weight Loss Pills & Supplements For Fast Fat Loss - Wolfson Brands Ltd
10/05/2025
Discover the best fat burners for men in 2025! Our expert guide ranks the top weight loss pills and supplements that deliver fast fat loss and shredded results. Find out which fat burners work and how to get the body [...]
6 Best Fat Burners For Women: Top Over the Counter and Online Pills and Fat Burning Supplements For Women Weight Loss In 2025 - Wolfson Brands
10/05/2025
Discover the 6 best fat burners for women in 2025. Top OTC & online weight loss pills from Wolfson Brands (UK) Limited to burn fat, boost energy & crush cravings fast. New York City, NY, May 10, 2025 (GLOBE [...]
Activists Mark Luigi Mangione’s Birthday With Aerial Protest as Times Square Billboard on Jury Rights Explodes Online
10/05/2025
Two independent campaigns in NYC spotlight healthcare and legal reform amid public outcry over Luigi Mangione’s case. Image by POPNYC NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Two major public actions are unfolding in [...]
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/05/2025
WOBURN, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of [...]
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/05/2025
PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets [...]
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/05/2025
BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 5, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock [...]
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
09/05/2025
CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its [...]
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/05/2025
SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
09/05/2025
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing ALS patients in [...]
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
09/05/2025
JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for [...]
Oculis Publishes Invitation to the Annual General Meeting
09/05/2025
ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at [...]
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
09/05/2025
- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months - Initiated utilization of share repurchase program - Cash [...]

Pages